Comphya SA: Company Profile

Background

Comphya SA, established in June 2017 and headquartered in Lausanne, Switzerland, is a medical device company specializing in the development of innovative solutions for erectile dysfunction (ED). As a spin-off from the École Polytechnique Fédérale de Lausanne (EPFL), Comphya's mission is to restore erectile function in patients unresponsive to oral medications, thereby enhancing their quality of life. The company's flagship product, CaverSTIM™, is the first implantable neurostimulator designed to address this unmet medical need.

Key Strategic Focus

Comphya's strategic focus centers on the development and commercialization of CaverSTIM™, targeting patients who do not respond to conventional oral ED treatments, such as those recovering from prostatectomy or with spinal cord injuries. By leveraging neuroprosthetic principles, the company aims to offer a physiological and superior alternative to existing therapies like intrapenile injections or penile implants. The primary markets include Europe, the United States, Australia, and Brazil, where clinical trials are currently underway.

Financials and Funding

Comphya has successfully secured multiple funding rounds to support its research and development initiatives:

Seed Investment Round (April 2019): Raised CHF 3 million to advance early-stage development.

Series A First Tranche (December 2024): Closed at CHF 4.35 million, combining converted convertible loans and new equity, to support ongoing clinical trials.

Series A Completion (July 2025): An oversubscribed round totaling CHF 7.5 million, facilitating the expansion of U.S. and Australian clinical programs following promising pilot data.

Notable investors include existing shareholders and new participants, with support from organizations like the Praxis Spinal Cord Institute, emphasizing the company's commitment to addressing spinal cord injury-related ED.

Pipeline Development

Comphya's primary product, CaverSTIM™, is progressing through various stages of clinical development:

Australia: Received regulatory approval in March 2023 for a pilot clinical trial assessing safety and preliminary efficacy in post-prostatectomy patients.

United States: Obtained FDA Investigational Device Exemption (IDE) approval in January 2025, with pilot studies initiated at Johns Hopkins University.

Brazil: Launched a clinical study in July 2023 focusing on spinal cord injury patients.

These trials aim to establish the safety and efficacy of CaverSTIM™, with pivotal U.S. trials planned for 2026.

Technological Platform and Innovation

CaverSTIM™ represents a groundbreaking approach in ED treatment:

Proprietary Technology: An implantable neurostimulation system comprising an implantable pulse generator (IPG) with a rechargeable battery and electronics that generate electrostimulation signals.

Scientific Methodology: The system includes two electrode arrays implanted in the pelvic cavity to stimulate the cavernous nerves, restoring natural erectile function.

AI-Driven Capabilities: While specific AI applications are not detailed, the device's design allows for personalized parameter adjustments via clinician and patient controllers, enhancing treatment customization.

Leadership Team

Comphya's leadership comprises experienced professionals:

Pim van Wesel, Ph.D. – Appointed CEO in May 2025, bringing extensive experience in guiding medical device companies through growth phases.

Steven Swinson, Ph.D. – Chairman of the Board, with over 35 years in healthcare leadership, including roles at Medtronic and GE Medical Systems.

Nikos Stergiopulos, Ph.D. – Co-founder and Chief Scientific Officer, Professor at EPFL, with expertise in hemodynamics and cardiovascular technology.

Rodrigo Fraga-Silva, Ph.D. – Co-founder and former CEO, with a background in pharmacology and over 10 years of experience in vascular biology and sexual medicine.

Mikael Sturny, Ph.D. – Co-founder and Chief Technology Officer, specializing in biomedical technologies and medical device development.

Fiona Joseph – Head of Clinical Affairs, a biomedical engineer with expertise in quality and regulatory affairs.

Leadership Changes

In May 2025, Pim van Wesel was appointed CEO, succeeding Rodrigo Fraga-Silva, who transitioned to focus on scientific and clinical development.

Competitor Profile

Market Insights and Dynamics

The global erectile dysfunction market is substantial, with a significant segment of patients unresponsive to oral medications. This unmet need presents opportunities for innovative therapies like CaverSTIM™.

Competitor Analysis

While specific competitors are not detailed, existing treatments include:

Oral Medications: Phosphodiesterase type 5 inhibitors (e.g., Viagra, Cialis) are first-line treatments but ineffective for some patients.

Intrapenile Injections: Invasive and often associated with discomfort and compliance issues.

Penile Implants: Surgical options with inherent risks and potential complications.

Comphya's CaverSTIM™ offers a less invasive, physiological alternative, positioning it favorably in the competitive landscape.

Strategic Collaborations and Partnerships

In October 2019, Comphya partnered with Cirtec Medical Corp. to develop CaverSTIM™, leveraging Cirtec's expertise in neurostimulation device development to expedite time-to-market and reduce technological risks.

Operational Insights

Comphya's strategic considerations include:

Market Position: Addressing a significant unmet need in ED treatment with a novel, less invasive solution.

Competitive Advantages: Offering a physiological approach that restores natural erectile function, differentiating CaverSTIM™ from existing therapies.

Strategic Opportunities and Future Directions

Comphya's roadmap includes:

Clinical Trials: Advancing ongoing studies in Australia, the U.S., and Brazil to establish safety and efficacy.

Regulatory Approvals: Pursuing necessary approvals to commercialize CaverSTIM™ in target markets.

Market Expansion: Exploring opportunities in additional regions and patient populations to broaden the impact of CaverSTIM™.

Contact Information

For more information, visit Comphya's official website: www.comphya.com

Note: Specific contact details such as address, phone number, and email are not provided in this profile.